MAM-36 and ABILHAND as outcome measures of multiple sclerosis hand disability: an observational study

被引:1
|
作者
Prada, Valeria [1 ]
Tacchino, Andrea [2 ]
Podda, Jessica [2 ]
Pedulla, Ludovico [3 ]
Konrad, Giovanna [3 ]
Battaglia, Mario A. [4 ]
Brichetto, Giampaolo [2 ,3 ]
Monti Bragadin, Margherita [2 ,3 ]
机构
[1] Univ Genoa, Dept Neurosci, Genet & Maternal & Infantile Sci DINOGMI, Ophthalmol,Rehabil, Genoa, Italy
[2] Italian Multiple Sclerosis Soc Res Fdn FISM, Genoa, Italy
[3] AISM Rehabil Ctr, Italian Multiple Sclerosis Soc, Genoa, Italy
[4] Univ Siena, Dept Physiopathol, Expt Med & Publ Hlth, Siena, Italy
关键词
Outcome assessment; health care; Multiple sclerosis; Upper extremity; Neurodegenerative diseases; QUALITY-OF-LIFE; MANUAL ABILITY; PSYCHOMETRIC VALIDATION; EXPANDED DISABILITY; STATUS SCALE; FATIGUE; HEALTH; QUESTIONNAIRE; IMPAIRMENT; DEXTERITY;
D O I
10.23736/S1973-9087.20.06446-1
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
BACKGROUND: Impaired upper limb functionality and dexterity are common in people with multiple sclerosis (PwMS) and lead to increased dependency and reduced quality of life. AIM: The aim of this study was to compare the ability of the Manual Abilites Measure 36 (MAM-36) and the ABILHAND questionnaire to recognize an involvement of the upper limbs in PwMS, and to compare their results with those of other patient reported outcomes (PRO) evaluating disability, functional independence, symptoms of anxiety and depression, fatigue and quality of life. DESIGN: The study design was observational. SETTING: The setting of the study was outpatient. POPULATION: The study population included fifty-one PwMS (mean age of 56.31 years, age range of 33-82 years, 72.5% of patients were females). METHODS: For each patient were collected MAM-36, ABILHAND questionnaire, expanded disability status scale (EDSS), Functional Independence measure (FIM), Hospital Anxiety and Depression Scale (HADS), Modified Fatigue Impact Scale (MFIS) and Life Satisfaction Index (LSI). RESULTS : A strong correlation between MAM-36 and the ABILHAND questionnaire (Spearman r: 0.79; P<0.0001) were found. We obtained a significant correlation between MAM-36 and EDSS (Spearman r: -0.5; P=0.0002), FIM (Spearman r: 0.55; P<0.0001); we did not observe a correlation with MFIS (Spearman r: -0.33; P=0.02); moreover we found a similar trend between ABILHAND and EDSS (Spearman r: -0.47; P=0.0005), FIM (Spearman r: 0.61; P<0.0001), MFIS (Spearman r: -0.41; P=0.002). CONCLUSIONS: In PwMS the assessment of upper limbs is fundamental since it closely related to the level of disability of the person. Both MAM-36 and ABILHAND Questionnaire are equally able to detect upper limb dysfunctions in PwMS. CLINICAL REHABILITATION IMPACT : Both MAM-36 and ABILHAND can be used for upper limbs evaluation, within a multidimensional approach that seems to be the best way to evaluate PwMS.
引用
收藏
页码:520 / 526
页数:7
相关论文
共 50 条
  • [41] The usefulness of evaluative outcome measures in patients with multiple sclerosis
    de Groot, V.
    Beckerman, H.
    Uitdehaag, B. M. J.
    de Vet, H. C. W.
    Lankhorst, G. J.
    Polman, C. H.
    Bouter, L. M.
    BRAIN, 2006, 129 : 2648 - 2659
  • [42] Imaging outcome measures for progressive multiple sclerosis trials
    Moccia, Marcello
    de Stefano, Nicola
    Barkhof, Frederik
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (12) : 1614 - 1626
  • [43] Outcome measures assisting treatment optimization in multiple sclerosis
    Gabriel Pardo
    Samantha Coates
    Darin T. Okuda
    Journal of Neurology, 2022, 269 : 1282 - 1297
  • [44] Immunomodulatory Therapy Slows Accumulation of Disability in Advanced Multiple Sclerosis: A Global Observational Cohort Study
    Kalincik, Tomas
    Lizak, Nathaniel
    NEUROLOGY, 2016, 86
  • [45] Prevalence of disability improvement as a potential outcome for multiple sclerosis trials
    Signori, Alessio
    Boffa, Giacomo
    Bovis, Francesca
    Mariottini, Alice
    Repice, Annamaria
    Inglese, Matilde
    Amato, Maria Pia
    Mancardi, Gianluigi
    Massacesi, Luca
    Saccardi, Riccardo
    Sormani, Maria Pia
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (05) : 706 - 711
  • [46] Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study
    Moser, Tobias
    Foettinger, Fabian
    Hitzl, Wolfgang
    Novotna, Bianka
    Berger, Thomas
    Bsteh, Gabriel
    Di Pauli, Franziska
    Hegen, Harald
    Kornek, Barbara
    Langenscheidt, Dieter
    Sellner, Johann
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (06): : 1442 - 1455
  • [47] Hand and arm function and predicting the disability status of patients with multiple sclerosis
    Heidari, Marzeih
    Nabavi, Seyedmassood
    Akbarfahimi, Malahat
    Taghizade, Ghorban
    Lajevardi, Laleh
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 753 - 753
  • [48] Lipid and brain volumetric measures in multiple sclerosis patients: findings from a large observational study
    Lorincz, Balazs
    Vrablik, Michal
    Murali, Ramanathan
    Havrdova, Eva Kubala
    Horakova, Dana
    Krasensky, Jan
    Vaneckova, Manuela
    Uher, Tomas
    ACTA NEUROLOGICA BELGICA, 2024, 124 (06) : 1981 - 1988
  • [49] Retinal measures correlate with cognitive and physical disability in early multiple sclerosis
    Nabil K. El Ayoubi
    Stephanie Ghassan
    Marianne Said
    Joelle Allam
    Hala Darwish
    Samia J. Khoury
    Journal of Neurology, 2016, 263 : 2287 - 2295
  • [50] Cortical Morphometric Measures Associate with Cortical Lesions and Disability in Multiple Sclerosis
    Parvathaneni, P.
    Beck, E. S.
    Maranzano, J.
    Wu, T.
    Nair, G.
    Reich, D.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 66 - 67